Wall Street analysts predict that Humana Inc (NYSE:HUM) will announce $2.18 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Humana’s earnings, with estimates ranging from $2.10 to $2.22. Humana posted earnings of $2.65 per share during the same quarter last year, which would suggest a negative year over year growth rate of 17.7%. The company is expected to announce its next earnings report on Wednesday, February 5th.
According to Zacks, analysts expect that Humana will report full year earnings of $17.77 per share for the current fiscal year, with EPS estimates ranging from $17.70 to $17.81. For the next financial year, analysts anticipate that the business will post earnings of $18.67 per share, with EPS estimates ranging from $18.35 to $18.84. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Humana.
Humana (NYSE:HUM) last released its earnings results on Wednesday, November 6th. The insurance provider reported $5.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.58 by $0.45. The company had revenue of $16.24 billion during the quarter, compared to analyst estimates of $16.15 billion. Humana had a return on equity of 22.32% and a net margin of 4.06%. Humana’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the company posted $4.58 earnings per share.
Several equities analysts have recently issued reports on HUM shares. Morgan Stanley reaffirmed a “buy” rating and issued a $360.00 target price (up from $337.00) on shares of Humana in a report on Monday, November 18th. Deutsche Bank began coverage on Humana in a report on Thursday, September 12th. They issued a “hold” rating and a $300.00 target price for the company. ValuEngine upgraded Humana from a “hold” rating to a “buy” rating in a research note on Friday, November 8th. Cantor Fitzgerald upgraded Humana from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $300.00 to $345.00 in a research note on Monday, August 12th. Finally, BMO Capital Markets downgraded Humana from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $345.00 to $290.00 in a research note on Monday, September 30th. One analyst has rated the stock with a sell rating, four have issued a hold rating and thirteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $324.82.
HUM stock opened at $338.25 on Tuesday. The firm has a market cap of $45.19 billion, a PE ratio of 23.25, a P/E/G ratio of 1.46 and a beta of 0.90. The company has a quick ratio of 1.83, a current ratio of 1.83 and a debt-to-equity ratio of 0.46. The business has a 50 day moving average of $310.57 and a 200-day moving average of $280.85. Humana has a 12-month low of $225.65 and a 12-month high of $345.71.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a $0.55 dividend. The ex-dividend date of this dividend is Monday, December 30th. This represents a $2.20 annualized dividend and a yield of 0.65%. Humana’s payout ratio is 15.12%.
Several large investors have recently bought and sold shares of HUM. Commonwealth Equity Services LLC lifted its position in shares of Humana by 13.7% during the second quarter. Commonwealth Equity Services LLC now owns 11,232 shares of the insurance provider’s stock worth $2,979,000 after acquiring an additional 1,355 shares in the last quarter. FDx Advisors Inc. lifted its position in shares of Humana by 9.8% during the second quarter. FDx Advisors Inc. now owns 1,346 shares of the insurance provider’s stock worth $357,000 after acquiring an additional 120 shares in the last quarter. AE Wealth Management LLC lifted its position in shares of Humana by 4.2% during the second quarter. AE Wealth Management LLC now owns 3,187 shares of the insurance provider’s stock worth $846,000 after acquiring an additional 128 shares in the last quarter. Whittier Trust Co. purchased a new stake in shares of Humana during the second quarter worth $27,000. Finally, Arden Trust Co purchased a new stake in shares of Humana during the second quarter worth $204,000. Hedge funds and other institutional investors own 94.01% of the company’s stock.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading: Operating Income
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.